First accepted therapy in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval relies on constructive Part III information from multinational and Japanese research in sufferers aged 12 years and older and a multinational pediatric examine in youngsters aged 4 to 11 yearsFirst approval of Joenja overlaying youngsters aged 4 to 11 with APDS
Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) at the moment introduced that Japan’s Ministry of Well being, Labour and Welfare (MHLW) has accepted Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the therapy of activated PI3K delta syndrome (APDS) in grownup and pediatric sufferers aged 4 years and older.
With this approval, Joenja turns into the primary therapy accepted in Japan particularly for APDS and the primary accepted therapy wherever globally, for kids aged 4 to 11 with the illness. Below an settlement with Pharming, OrphanPacific, Inc. serves because the Advertising and marketing Authorization Holder for Joenja in Japan and in collaboration with Pharming, is accountable for provide and distribution of the product. The launch of Joenja is anticipated following settlement with the MHLW on its Nationwide Well being Insurance coverage drug worth.
Professor Hirokazu Kanegane, MD, PhD, Division of Baby Well being and Improvement on the Graduate College of Medical and Dental Sciences, Institute of Science Tokyo commented:“Patients with APDS in Japan have until now relied largely on supportive care, so this approval marks an important step forward for the APDS community. This approval introduces the first approved targeted treatment option for this rare primary immunodeficiency in Japan, and has the potential to help reduce the burden of disease for patients and their families.”
Leverne Marsh, Chief Industrial Officer of Pharming, commented:“The approval of Joenja for patients as young as 4 years of age is an important milestone for the APDS community in Japan. As the first treatment approved specifically for APDS in the country, it is the only targeted treatment option for patients and families affected by this rare and progressive disease. It also marks the first approval globally for children aged 4 to 11 with APDS. Together with OrphanPacific, we look forward to working through the next steps to help make Joenja available to patients in Japan as quickly as possible.”
More Read
The MHLW primarily based the approval on information from Pharming’s Part III medical program for leniolisib in APDS, together with the worldwide, randomized, placebo-controlled examine in sufferers aged 12 years and older, by which leniolisib met its co-primary endpoints by considerably lowering lymphadenopathy and considerably rising the proportion of naïve B cells out of whole B cells. This displays a clinically related influence on immune dysregulation and deficiency that are hallmarks of APDS. Leniolisib was typically properly tolerated with the most typical opposed reactions (>10%) being headache, sinusitis, and atopic dermatitis. Supporting Part III proof additionally included the open-label Japanese examine in sufferers aged 12 years and older, in addition to constructive information from the open-label, multinational Part III examine in youngsters aged 4 to 11 years, together with websites in Japan, which confirmed enhancements over 12 weeks in lowered lymphadenopathy and elevated proportion of naïve B cells from whole B cells.
The Japanese Prescription drugs and Medical Units Company (PMDA) evaluated the applying below the Precedence Overview pathway following the Orphan Drug Designation granted by the MHLW in Might 2023.
Joenja® is accepted and marketed in america and the UK for sufferers 12 years of age and older with APDS.
More Read
About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) APDS is a uncommon main immunodeficiency that was first characterised in 2013. APDS is brought on by variants in both of two recognized genes generally known as PIK3CD or PIK3R1, that are important to the event and performance of immune cells within the physique. Variants of those genes result in hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and performance correctly, resulting in immunodeficiency and dysregulation1,2,3 APDS is characterised by a wide range of signs, together with extreme, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 As a result of these signs will be related to a wide range of situations, together with different main immunodeficiencies, it has been reported that folks with APDS are incessantly misdiagnosed and endure a median 7-year diagnostic delay.6 As APDS is a progressive illness, this delay might result in an accumulation of harm over time, together with everlasting lung injury and lymphoma.4-7 A definitive analysis will be made by means of genetic testing. APDS impacts roughly 1 to 2 folks per million worldwide.8
About Joenja® (leniolisib)Leniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor accepted as the primary and solely focused therapy of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) within the U.S., U.Okay., Australia and Israel in grownup and pediatric sufferers 12 years of age and older and in Japan for sufferers 4 years of age and older. Leniolisib inhibits the manufacturing of phosphatidylinositol-3-4-5-trisphosphate, which serves as an vital mobile messenger and regulates a large number of cell features resembling proliferation, differentiation, cytokine manufacturing, cell survival, angiogenesis, and metabolism. Outcomes from a randomized, placebo-controlled Part III medical trial demonstrated statistically important enchancment within the coprimary endpoints, reflecting a good influence on the immune dysregulation and deficiency seen in these sufferers, and open label extension information has supported the security and tolerability of long-term leniolisib administration.9,10
Leniolisib is presently below regulatory overview for the therapy of APDS within the European Financial Space, Canada and several other different international locations. Leniolisib can also be being evaluated in two Part II medical trials in main immunodeficiencies (PIDs) with immune dysregulation. The protection and efficacy of leniolisib has not been established for PIDs with immune dysregulation past APDS.
About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a world biopharmaceutical firm devoted to reworking the lives of sufferers with uncommon, debilitating, and life-threatening ailments. We’re creating and commercializing a portfolio of modern medicines, together with small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a major proportion of its workers primarily based within the U.S.
For extra data, go to www.pharming.com and discover us on LinkedIn. Ahead-looking Statements This press launch might include forward-looking statements. Ahead-looking statements are statements of future expectations which are primarily based on administration’s present expectations and assumptions and contain identified and unknown dangers and uncertainties that might trigger precise outcomes, efficiency, or occasions to vary materially from these expressed or implied in these statements. These forward-looking statements are recognized by their use of phrases and phrases resembling “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and related phrases and phrases. Examples of forward-looking statements might embrace statements with respect to timing and progress of Pharming’s preclinical research and medical trials of its product candidates, Pharming’s medical and business prospects, and Pharming’s expectations concerning its projected working capital necessities and money sources, which statements are topic to quite a few dangers, uncertainties and assumptions, together with, however not restricted to the scope, progress and growth of Pharming’s medical trials and ramifications for the associated fee thereof; and medical, scientific, regulatory, business, aggressive and technical developments. In mild of those dangers and uncertainties, and different dangers and uncertainties which are described in Pharming’s 2024 Annual Report and the Annual Report on Type 20-F for the 12 months ended December 31, 2024, filed with the U.S. Securities and Change Fee, the occasions and circumstances mentioned in such forward-looking statements might not happen, and Pharming’s precise outcomes may differ materially and adversely from these anticipated or implied thereby. All forward-looking statements contained on this press launch are expressly certified of their entirety by the cautionary statements contained or referred to on this part. Readers mustn’t place undue reliance on forward-looking statements. Any forward-looking statements communicate solely as of the date of this press launch and are primarily based on data accessible to Pharming as of the date of this launch. Pharming doesn’t undertake any obligation to publicly replace or revise any forward-looking assertion because of new data, future occasions or different data.
Inside InformationThis press launch pertains to the disclosure of knowledge that qualifies, or might have certified, as inside data throughout the which means of Article 7(1) of the EU Market Abuse Regulation.
More Read
References
Lucas CL, et al. Nat Immunol. 2014;15(1):88-97.Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.Maccari ME, et al. Entrance Immunol. 2018;9:543.Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333.Condliffe AM, Chandra A. Entrance Immunol. 2018;9:338.Vanselow S, et al. Frontiers in Immunology. 2023;14:1208567. Rao VK, et al Blood. 2023 Mar 2;141(9):971-983.Rao VK, et al. J Allergy Clin Immunol 2024;153:265-74.
U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)T: +1 (917) 882-9038
Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)T: +31 6 53 81 64 27
FINAL_Pharming Group publicizes approval of Joenja® in Japan_EN_24Mar2026
